Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 12.23
CPIX's Cash-to-Debt is ranked higher than
59% of the 733 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.95 vs. CPIX: 12.23 )
Ranked among companies with meaningful Cash-to-Debt only.
CPIX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.16  Med: 13.38 Max: No Debt
Current: 12.23
Equity-to-Asset 0.78
CPIX's Equity-to-Asset is ranked higher than
77% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. CPIX: 0.78 )
Ranked among companies with meaningful Equity-to-Asset only.
CPIX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42  Med: 0.81 Max: 0.91
Current: 0.78
0.42
0.91
Piotroski F-Score: 4
Altman Z-Score: 4.29
Beneish M-Score: -2.46
WACC vs ROIC
7.44%
-3.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -4.34
CPIX's Operating Margin % is ranked lower than
77% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.19 vs. CPIX: -4.34 )
Ranked among companies with meaningful Operating Margin % only.
CPIX' s Operating Margin % Range Over the Past 10 Years
Min: -11.87  Med: 13.72 Max: 23.96
Current: -4.34
-11.87
23.96
Net Margin % -2.86
CPIX's Net Margin % is ranked lower than
76% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. CPIX: -2.86 )
Ranked among companies with meaningful Net Margin % only.
CPIX' s Net Margin % Range Over the Past 10 Years
Min: -6.57  Med: 6.84 Max: 14.41
Current: -2.86
-6.57
14.41
ROE % -1.26
CPIX's ROE % is ranked lower than
72% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. CPIX: -1.26 )
Ranked among companies with meaningful ROE % only.
CPIX' s ROE % Range Over the Past 10 Years
Min: -2.55  Med: 5.08 Max: 29.02
Current: -1.26
-2.55
29.02
ROA % -1.04
CPIX's ROA % is ranked lower than
70% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.38 vs. CPIX: -1.04 )
Ranked among companies with meaningful ROA % only.
CPIX' s ROA % Range Over the Past 10 Years
Min: -2.26  Med: 3.62 Max: 15.88
Current: -1.04
-2.26
15.88
ROC (Joel Greenblatt) % -39.69
CPIX's ROC (Joel Greenblatt) % is ranked lower than
79% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.39 vs. CPIX: -39.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CPIX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -151.51  Med: 86.86 Max: 1721.07
Current: -39.69
-151.51
1721.07
3-Year Revenue Growth Rate 5.20
CPIX's 3-Year Revenue Growth Rate is ranked lower than
52% of the 604 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. CPIX: 5.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CPIX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -7.4  Med: 5.2 Max: 47.3
Current: 5.2
-7.4
47.3
3-Year EPS without NRI Growth Rate -18.30
CPIX's 3-Year EPS without NRI Growth Rate is ranked lower than
80% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. CPIX: -18.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CPIX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.9  Med: -16.3 Max: 34.2
Current: -18.3
-48.9
34.2
» CPIX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CPIX Guru Trades in Q1 2016

John Rogers 1,976,671 sh (+39.53%)
Jim Simons 222,600 sh (+2.49%)
» More
Q2 2016

CPIX Guru Trades in Q2 2016

Jim Simons 235,300 sh (+5.71%)
John Rogers 1,992,613 sh (+0.81%)
» More
Q3 2016

CPIX Guru Trades in Q3 2016

Jim Simons 247,100 sh (+5.01%)
John Rogers 2,049,760 sh (+2.87%)
» More
Q4 2016

CPIX Guru Trades in Q4 2016

Jim Simons 257,000 sh (+4.01%)
John Rogers 1,824,580 sh (-10.99%)
» More
» Details

Insider Trades

Latest Guru Trades with CPIX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:MSLI, NAS:ADMP, OTCPK:ZOMHF, NAS:SPHS, NAS:EPIX, NAS:STDY, NAS:AGRX, OTCPK:CPHRF, NAS:TYHT, NAS:BPTH, NAS:LPCN, NAS:DRRX, NAS:GALT, OTCPK:SENZ, NAS:SCYX, OTCPK:WUYIF, OTCPK:ELTP, NAS:CPRX, OTCPK:MGCLF, NAS:ARLZ » details
Traded in other countries:CBJ.Germany,
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the acquisition, development and commercialization of branded prescription products. Its target markets are hospital acute care and gastroenterology.

Cumberland Pharmaceuticals Inc., was incorporated in Tennessee on January 6, 1999. It is a specialty pharmaceutical company which is engaged in the acquisition, development and commercialization of branded prescription products. It operates in a single operating segment of specialty pharmaceuticals products. Its product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose (lactulose) for Oral Solution, a prescription laxative, and Hepatoren (ifetroban) injection, a Phase II candidate for the treatment of critically ill hospitalized patients suffering from hepatorenal syndrome (HRS). The Company's target markets are hospital acute care and gastroenterology, which are characterized by concentrated physician bases that it believe can be penetrated effectively by relatively small, targeted sales forces. The Company markets and sells its products through its dedicated hospital and gastroenterology sales forces in the United States, which together comprised more than 65 sales representatives and managers as of March 1, 2013. Acetadote is an intravenous formulation of N-acetylcysteine, or NAC, indicated for the treatment of acetaminophen poisoning. Caldolor, its intravenous formulation of ibuprofen, was the first injectable product approved in the United States for the treatment of both pain and fever. Kristalose is a prescription laxative administered orally for the treatment of constipation. Hepatoren is in Phase II clinical development. Pharmaceutical companies are subject to extensive regulation by national, state, and local agencies in the U.S. and additional regulations in other countries in which do business. It promotes Acetadote and Caldolor through its dedicated hospital sales team and currently utilize two distinct sales teams to address its primary target markets: a hospital sales force for the acute care market and a field sales force for the gastroenterology market. It competes with the product attributes such as efficacy, safety, ease-of-use and cost-effectiveness.

Ratios

vs
industry
vs
history
PB Ratio 1.56
CPIX's PB Ratio is ranked higher than
79% of the 898 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. CPIX: 1.56 )
Ranked among companies with meaningful PB Ratio only.
CPIX' s PB Ratio Range Over the Past 10 Years
Min: 0.9  Med: 1.29 Max: 4.83
Current: 1.56
0.9
4.83
PS Ratio 3.50
CPIX's PS Ratio is ranked lower than
55% of the 867 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. CPIX: 3.50 )
Ranked among companies with meaningful PS Ratio only.
CPIX' s PS Ratio Range Over the Past 10 Years
Min: 1.66  Med: 2.63 Max: 6.8
Current: 3.5
1.66
6.8
Price-to-Operating-Cash-Flow 196.10
CPIX's Price-to-Operating-Cash-Flow is ranked lower than
95% of the 369 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.28 vs. CPIX: 196.10 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CPIX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.4  Med: 22.29 Max: 1583.33
Current: 196.1
11.4
1583.33
EV-to-EBITDA 57.23
CPIX's EV-to-EBITDA is ranked lower than
88% of the 783 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.99 vs. CPIX: 57.23 )
Ranked among companies with meaningful EV-to-EBITDA only.
CPIX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -56.6  Med: 8.7 Max: 60.51
Current: 57.23
-56.6
60.51
Shiller PE Ratio 44.93
CPIX's Shiller PE Ratio is ranked higher than
57% of the 164 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.73 vs. CPIX: 44.93 )
Ranked among companies with meaningful Shiller PE Ratio only.
CPIX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 21.7  Med: 26.16 Max: 46.46
Current: 44.93
21.7
46.46
Current Ratio 4.43
CPIX's Current Ratio is ranked higher than
76% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. CPIX: 4.43 )
Ranked among companies with meaningful Current Ratio only.
CPIX' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 5.08 Max: 13.23
Current: 4.43
1.45
13.23
Quick Ratio 4.07
CPIX's Quick Ratio is ranked higher than
77% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.75 vs. CPIX: 4.07 )
Ranked among companies with meaningful Quick Ratio only.
CPIX' s Quick Ratio Range Over the Past 10 Years
Min: 1.38  Med: 4.74 Max: 12.35
Current: 4.07
1.38
12.35
Days Inventory 289.37
CPIX's Days Inventory is ranked lower than
92% of the 642 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. CPIX: 289.37 )
Ranked among companies with meaningful Days Inventory only.
CPIX' s Days Inventory Range Over the Past 10 Years
Min: 110.73  Med: 381.63 Max: 636.33
Current: 289.37
110.73
636.33
Days Sales Outstanding 81.01
CPIX's Days Sales Outstanding is ranked lower than
52% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.21 vs. CPIX: 81.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
CPIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.88  Med: 51.09 Max: 81.01
Current: 81.01
30.88
81.01
Days Payable 492.28
CPIX's Days Payable is ranked higher than
98% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. CPIX: 492.28 )
Ranked among companies with meaningful Days Payable only.
CPIX' s Days Payable Range Over the Past 10 Years
Min: 103.04  Med: 225.25 Max: 496.99
Current: 492.28
103.04
496.99

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 3.70
CPIX's 3-Year Average Share Buyback Ratio is ranked higher than
98% of the 446 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. CPIX: 3.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CPIX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -7  Med: 2.1 Max: 5.1
Current: 3.7
-7
5.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 3.78
CPIX's Price-to-Net-Cash is ranked higher than
84% of the 268 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.85 vs. CPIX: 3.78 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CPIX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.37  Med: 2.33 Max: 5.81
Current: 3.78
1.37
5.81
Price-to-Net-Current-Asset-Value 2.50
CPIX's Price-to-Net-Current-Asset-Value is ranked higher than
89% of the 615 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.44 vs. CPIX: 2.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CPIX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.07  Med: 1.78 Max: 4.44
Current: 2.5
1.07
4.44
Price-to-Tangible-Book 2.22
CPIX's Price-to-Tangible-Book is ranked higher than
73% of the 830 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.52 vs. CPIX: 2.22 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CPIX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.04  Med: 1.64 Max: 4.27
Current: 2.22
1.04
4.27
Price-to-Intrinsic-Value-Projected-FCF 1.51
CPIX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
75% of the 422 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. CPIX: 1.51 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CPIX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.73  Med: 1.13 Max: 1.56
Current: 1.51
0.73
1.56
Price-to-Median-PS-Value 1.33
CPIX's Price-to-Median-PS-Value is ranked lower than
51% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.18 vs. CPIX: 1.33 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CPIX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.65  Med: 1.04 Max: 2.07
Current: 1.33
0.65
2.07
Earnings Yield (Greenblatt) % -1.85
CPIX's Earnings Yield (Greenblatt) % is ranked lower than
74% of the 1021 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.62 vs. CPIX: -1.85 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CPIX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.23  Med: 7.7 Max: 79.2
Current: -1.85
-2.23
79.2
Forward Rate of Return (Yacktman) % -1.05
CPIX's Forward Rate of Return (Yacktman) % is ranked lower than
70% of the 367 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.75 vs. CPIX: -1.05 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CPIX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.05  Med: 3.6 Max: 18
Current: -1.05
-1.05
18

More Statistics

Revenue (TTM) (Mil) $33.03
EPS (TTM) $ -0.06
Beta0.69
Short Percentage of Float0.89%
52-Week Range $4.27 - 6.73
Shares Outstanding (Mil)16.01
» More Articles for CPIX

Headlines

Articles On GuruFocus.com
Micro Cap Value Discovery Jul 05 2016 
Speculative Options Buys Apr 29 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 15 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 16 2010 
Cumberland Pharmaceuticals Inc. Reports Operating Results (10-Q) May 17 2010 

More From Other Websites
4:18 pm Cumberland Pharma announces the the publication of a trial providing evidence that using... Mar 27 2017
Caldolor® Demonstrates Significant Post Surgical Pain Reduction and Decrease in Opioid Use Mar 27 2017
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K/A, Changes in Registrant's Certifying Accountant,... Mar 22 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of... Mar 22 2017
Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21,... Mar 21 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of... Mar 17 2017
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant Mar 16 2017
CUMBERLAND PHARMACEUTICALS INC Financials Mar 16 2017
Cumberland Pharmaceuticals, Inc. :CPIX-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017 Mar 15 2017
CUMBERLAND PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Mar 13 2017
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition Mar 10 2017
Edited Transcript of CPIX earnings conference call or presentation 7-Mar-17 9:30pm GMT Mar 07 2017
Cumberland reports 4Q loss Mar 07 2017
Cumberland reports 4Q loss Mar 07 2017
Cumberland Pharmaceuticals Reports Fourth Quarter And Full Year 2016 Financial Results Mar 07 2017
Q4 2016 Cumberland Pharmaceuticals Inc Earnings Release - After Market Close Mar 07 2017
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2016 Financial Results Feb 28 2017
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Feb 10 2017
Caldolor® Pediatric Fever Study Published Supporting Its Efficacy, Safety And Pharmacokinetics Feb 07 2017
CUMBERLAND PHARMACEUTICALS INC Files SEC form 8-K, Other Events Feb 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)